Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
This clinical trial, in which the study group was made up of black patients with heart failure, showed that the combination of isosorbide dinitrate and hydralazine significantly improves survival when added to standard therapy for heart failure. In this clinical trial of black patients with heart fa...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-11, Vol.351 (20), p.2049-2057 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2057 |
|---|---|
| container_issue | 20 |
| container_start_page | 2049 |
| container_title | The New England journal of medicine |
| container_volume | 351 |
| creator | Taylor, Malcolm Taylor, Anne L Ziesche, Susan Yancy, Clyde Carson, Peter D'Agostino, Ralph Ferdinand, Keith Adams, Kirkwood Sabolinski, Michael Worcel, Manuel Cohn, Jay N |
| description | This clinical trial, in which the study group was made up of black patients with heart failure, showed that the combination of isosorbide dinitrate and hydralazine significantly improves survival when added to standard therapy for heart failure.
In this clinical trial of black patients with heart failure, the combination of isosorbide dinitrate and hydralazine significantly improved survival when added to standard therapy.
Neurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure.
1
–
10
Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure.
11
–
27
Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT . . . |
| doi_str_mv | 10.1056/NEJMoa042934 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223934690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746249061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-2f63adb23d3442213b526a577eb42e5fc4e967714614ed59c61546331c20d2053</originalsourceid><addsrcrecordid>eNpt0DtPwzAUBWALgWgpbMzIQrAR8DtkhNLSovIYYI4cxxEuiV3sRKj8eowaqQzc5S6fzr06ABxjdIkRF1dPk4dHJxEjGWU7YIg5pQljSOyCIULkOmFpRgfgIIQlioNZtg8GmEd1zfEQvIxdUxgrW-MsdBWcBxecL0yp4Z2xpvWy1VDaEs7WpZe1_DZWQ2PhbS3VR4Bfpn2HMy19C6fS1J3Xh2CvknXQR_0egbfp5HU8SxbP9_PxzSJRPKVtQipBZVkQWlLGCMG04ERInqa6YETzSjGdiTTFTGCmS54pgTkTlGJFUEkQpyNwusldeffZ6dDmS9d5G0_mhNDYhchQRBcbpLwLwesqX3nTSL_OMcp_28v_thf5SZ_ZFY0ut7ivK4LzHsigZF15aZUJWydIfDcj0Z1tXNOE3Opl8_-9H9eOgGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223934690</pqid></control><display><type>article</type><title>Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Taylor, Malcolm ; Taylor, Anne L ; Ziesche, Susan ; Yancy, Clyde ; Carson, Peter ; D'Agostino, Ralph ; Ferdinand, Keith ; Adams, Kirkwood ; Sabolinski, Michael ; Worcel, Manuel ; Cohn, Jay N</creator><creatorcontrib>Taylor, Malcolm ; Taylor, Anne L ; Ziesche, Susan ; Yancy, Clyde ; Carson, Peter ; D'Agostino, Ralph ; Ferdinand, Keith ; Adams, Kirkwood ; Sabolinski, Michael ; Worcel, Manuel ; Cohn, Jay N ; African-American Heart Failure Trial Investigators</creatorcontrib><description>This clinical trial, in which the study group was made up of black patients with heart failure, showed that the combination of isosorbide dinitrate and hydralazine significantly improves survival when added to standard therapy for heart failure.
In this clinical trial of black patients with heart failure, the combination of isosorbide dinitrate and hydralazine significantly improved survival when added to standard therapy.
Neurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure.
1
–
10
Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure.
11
–
27
Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa042934</identifier><identifier>PMID: 15533851</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; African Americans ; African Continental Ancestry Group ; Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular disease ; Clinical trials ; Double-Blind Method ; Drug Combinations ; Drug therapy ; Drug Therapy, Combination ; Female ; General aspects ; Heart ; Heart Failure - drug therapy ; Heart Failure - ethnology ; Heart Failure - mortality ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Hydralazine - adverse effects ; Hydralazine - therapeutic use ; Isosorbide Dinitrate - adverse effects ; Isosorbide Dinitrate - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Nitric Oxide Donors - adverse effects ; Nitric Oxide Donors - therapeutic use ; Quality of Life ; Survival Analysis ; Treatment Outcome ; Vasodilator Agents - adverse effects ; Vasodilator Agents - therapeutic use</subject><ispartof>The New England journal of medicine, 2004-11, Vol.351 (20), p.2049-2057</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-2f63adb23d3442213b526a577eb42e5fc4e967714614ed59c61546331c20d2053</citedby><cites>FETCH-LOGICAL-c573t-2f63adb23d3442213b526a577eb42e5fc4e967714614ed59c61546331c20d2053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa042934$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa042934$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16261492$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15533851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, Malcolm</creatorcontrib><creatorcontrib>Taylor, Anne L</creatorcontrib><creatorcontrib>Ziesche, Susan</creatorcontrib><creatorcontrib>Yancy, Clyde</creatorcontrib><creatorcontrib>Carson, Peter</creatorcontrib><creatorcontrib>D'Agostino, Ralph</creatorcontrib><creatorcontrib>Ferdinand, Keith</creatorcontrib><creatorcontrib>Adams, Kirkwood</creatorcontrib><creatorcontrib>Sabolinski, Michael</creatorcontrib><creatorcontrib>Worcel, Manuel</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>African-American Heart Failure Trial Investigators</creatorcontrib><title>Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>This clinical trial, in which the study group was made up of black patients with heart failure, showed that the combination of isosorbide dinitrate and hydralazine significantly improves survival when added to standard therapy for heart failure.
In this clinical trial of black patients with heart failure, the combination of isosorbide dinitrate and hydralazine significantly improved survival when added to standard therapy.
Neurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure.
1
–
10
Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure.
11
–
27
Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT . . .</description><subject>Adult</subject><subject>African Americans</subject><subject>African Continental Ancestry Group</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Clinical trials</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>General aspects</subject><subject>Heart</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - ethnology</subject><subject>Heart Failure - mortality</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Humans</subject><subject>Hydralazine - adverse effects</subject><subject>Hydralazine - therapeutic use</subject><subject>Isosorbide Dinitrate - adverse effects</subject><subject>Isosorbide Dinitrate - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nitric Oxide Donors - adverse effects</subject><subject>Nitric Oxide Donors - therapeutic use</subject><subject>Quality of Life</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Vasodilator Agents - adverse effects</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0DtPwzAUBWALgWgpbMzIQrAR8DtkhNLSovIYYI4cxxEuiV3sRKj8eowaqQzc5S6fzr06ABxjdIkRF1dPk4dHJxEjGWU7YIg5pQljSOyCIULkOmFpRgfgIIQlioNZtg8GmEd1zfEQvIxdUxgrW-MsdBWcBxecL0yp4Z2xpvWy1VDaEs7WpZe1_DZWQ2PhbS3VR4Bfpn2HMy19C6fS1J3Xh2CvknXQR_0egbfp5HU8SxbP9_PxzSJRPKVtQipBZVkQWlLGCMG04ERInqa6YETzSjGdiTTFTGCmS54pgTkTlGJFUEkQpyNwusldeffZ6dDmS9d5G0_mhNDYhchQRBcbpLwLwesqX3nTSL_OMcp_28v_thf5SZ_ZFY0ut7ivK4LzHsigZF15aZUJWydIfDcj0Z1tXNOE3Opl8_-9H9eOgGE</recordid><startdate>20041111</startdate><enddate>20041111</enddate><creator>Taylor, Malcolm</creator><creator>Taylor, Anne L</creator><creator>Ziesche, Susan</creator><creator>Yancy, Clyde</creator><creator>Carson, Peter</creator><creator>D'Agostino, Ralph</creator><creator>Ferdinand, Keith</creator><creator>Adams, Kirkwood</creator><creator>Sabolinski, Michael</creator><creator>Worcel, Manuel</creator><creator>Cohn, Jay N</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20041111</creationdate><title>Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure</title><author>Taylor, Malcolm ; Taylor, Anne L ; Ziesche, Susan ; Yancy, Clyde ; Carson, Peter ; D'Agostino, Ralph ; Ferdinand, Keith ; Adams, Kirkwood ; Sabolinski, Michael ; Worcel, Manuel ; Cohn, Jay N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-2f63adb23d3442213b526a577eb42e5fc4e967714614ed59c61546331c20d2053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>African Americans</topic><topic>African Continental Ancestry Group</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Clinical trials</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>General aspects</topic><topic>Heart</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - ethnology</topic><topic>Heart Failure - mortality</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Humans</topic><topic>Hydralazine - adverse effects</topic><topic>Hydralazine - therapeutic use</topic><topic>Isosorbide Dinitrate - adverse effects</topic><topic>Isosorbide Dinitrate - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nitric Oxide Donors - adverse effects</topic><topic>Nitric Oxide Donors - therapeutic use</topic><topic>Quality of Life</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Vasodilator Agents - adverse effects</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Malcolm</creatorcontrib><creatorcontrib>Taylor, Anne L</creatorcontrib><creatorcontrib>Ziesche, Susan</creatorcontrib><creatorcontrib>Yancy, Clyde</creatorcontrib><creatorcontrib>Carson, Peter</creatorcontrib><creatorcontrib>D'Agostino, Ralph</creatorcontrib><creatorcontrib>Ferdinand, Keith</creatorcontrib><creatorcontrib>Adams, Kirkwood</creatorcontrib><creatorcontrib>Sabolinski, Michael</creatorcontrib><creatorcontrib>Worcel, Manuel</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>African-American Heart Failure Trial Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Malcolm</au><au>Taylor, Anne L</au><au>Ziesche, Susan</au><au>Yancy, Clyde</au><au>Carson, Peter</au><au>D'Agostino, Ralph</au><au>Ferdinand, Keith</au><au>Adams, Kirkwood</au><au>Sabolinski, Michael</au><au>Worcel, Manuel</au><au>Cohn, Jay N</au><aucorp>African-American Heart Failure Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-11-11</date><risdate>2004</risdate><volume>351</volume><issue>20</issue><spage>2049</spage><epage>2057</epage><pages>2049-2057</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>This clinical trial, in which the study group was made up of black patients with heart failure, showed that the combination of isosorbide dinitrate and hydralazine significantly improves survival when added to standard therapy for heart failure.
In this clinical trial of black patients with heart failure, the combination of isosorbide dinitrate and hydralazine significantly improved survival when added to standard therapy.
Neurohormonal inhibitors alone or in combination slow the progression of left ventricular dysfunction, retarding the structural remodeling of the left ventricle that characterizes chronic heart failure and reducing the rates of death and complications among patients with heart failure.
1
–
10
Endothelial dysfunction, impaired bioavailability of nitric oxide, and increased oxidant stress also occur in patients with congestive heart failure and contribute to the remodeling process in experimental and clinical models of heart failure.
11
–
27
Augmentation of nitric oxide may therefore be an alternative or supplemental approach to slow or reverse progressive heart failure. The first Vasodilator Heart Failure Trial (V-HeFT . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>15533851</pmid><doi>10.1056/NEJMoa042934</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-11, Vol.351 (20), p.2049-2057 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223934690 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult African Americans African Continental Ancestry Group Aged Biological and medical sciences Cardiology. Vascular system Cardiovascular disease Clinical trials Double-Blind Method Drug Combinations Drug therapy Drug Therapy, Combination Female General aspects Heart Heart Failure - drug therapy Heart Failure - ethnology Heart Failure - mortality Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Hydralazine - adverse effects Hydralazine - therapeutic use Isosorbide Dinitrate - adverse effects Isosorbide Dinitrate - therapeutic use Male Medical sciences Middle Aged Nitric Oxide Donors - adverse effects Nitric Oxide Donors - therapeutic use Quality of Life Survival Analysis Treatment Outcome Vasodilator Agents - adverse effects Vasodilator Agents - therapeutic use |
| title | Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A43%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20Isosorbide%20Dinitrate%20and%20Hydralazine%20in%20Blacks%20with%20Heart%20Failure&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Taylor,%20Malcolm&rft.aucorp=African-American%20Heart%20Failure%20Trial%20Investigators&rft.date=2004-11-11&rft.volume=351&rft.issue=20&rft.spage=2049&rft.epage=2057&rft.pages=2049-2057&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa042934&rft_dat=%3Cproquest_cross%3E746249061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223934690&rft_id=info:pmid/15533851&rfr_iscdi=true |